Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis.

Neuroblastoma / genetics N-Myc Proto-Oncogene Protein / genetics Animals Mice Humans Carcinogenesis / genetics Golgi Apparatus / metabolism Mice, Transgenic Cell Line, Tumor Gene Expression Regulation, Neoplastic

Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
14 Oct 2024
Historique:
received: 12 07 2023
accepted: 16 09 2024
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 14 10 2024
Statut: epublish

Résumé

MYCN amplification predicts poor prognosis in childhood neuroblastoma. To identify MYCN oncogenic signal dependencies we performed N-ethyl-N-nitrosourea (ENU) mutagenesis on the germline of neuroblastoma-prone TH-MYCN transgenic mice to generate founders which had lost tumorigenesis. Sequencing of the mutant mouse genomes identified the Ring Finger Protein 121 (RNF121

Identifiants

DOI: 10.1038/s42003-024-06899-8 PMID: 39402275
pubmed: 39402275
doi: 10.1038/s42003-024-06899-8
pii: 10.1038/s42003-024-06899-8
doi:

Substances chimiques

N-Myc Proto-Oncogene Protein 0
MYCN protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1322

Subventions

Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP1125171
Organisme : Cancer Council NSW (Cancer Council New South Wales)
ID : RG21-08
Organisme : Cancer Council NSW (Cancer Council New South Wales)
ID : RG214491

Informations de copyright

© 2024. The Author(s).

Références

Darom, A., Bening-Abu-Shach, U. & Broday, L. RNF-121 is an endoplasmic reticulum-membrane E3 ubiquitin ligase involved in the regulation of beta-integrin. Mol. Biol. Cell 21, 1788–1798 (2010).
pubmed: 20357004 pmcid: 2877638 doi: 10.1091/mbc.e09-09-0774
Zhao, Y., Hongdu, B., Ma, D. & Chen, Y. Really interesting new gene finger protein 121 is a novel Golgi-localized membrane protein that regulates apoptosis. Acta Biochim. Biophys. Sin. 46, 668–674 (2014).
pubmed: 24928685 doi: 10.1093/abbs/gmu047
Ogino, K. et al. RING finger protein 121 facilitates the degradation and membrane localization of voltage-gated sodium channels. Proc. Natl Acad. Sci. USA 112, 2859–2864 (2015).
pubmed: 25691753 pmcid: 4352840 doi: 10.1073/pnas.1414002112
Zemirli, N., Pourcelot, M., Dogan, N., Vazquez, A. & Arnoult, D. The E3 ubiquitin ligase RNF121 is a positive regulator of NF-κB activation. Cell Commun. Signal. 12, 72 (2014).
pubmed: 25388546 pmcid: 4232610
Zeng, Y. et al. Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. Oncotarget 8, 20103–20112 (2017).
pubmed: 28223545 pmcid: 5386747 doi: 10.18632/oncotarget.15384
Lee, N. S. et al. Ring finger protein 126 (RNF126) suppresses ionizing radiation-induced p53-binding protein 1 (53BP1) focus formation. J. Biol. Chem. 293, 588–598 (2018).
pubmed: 29167269 doi: 10.1074/jbc.M116.765602
Gao, Y. et al. Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-β/catenin signaling pathway. Stem Cell Res. Ther. 8, 98 (2017).
pubmed: 28446252 pmcid: 5406878 doi: 10.1186/s13287-017-0548-8
Xiang, P., Sun, Y., Liu, Y., Shu, Q. & Zhu, Y. Really interesting new gene finger protein 121 is a tumor suppressor of renal cell carcinoma. Gene 676, 322–328 (2018).
pubmed: 30149063 doi: 10.1016/j.gene.2018.08.067
Jiang, Z. et al. Circ-RNF121 regulates tumor progression and glucose metabolism by miR-1224-5p/FOXM1 axis in colorectal cancer. Cancer Cell Int. 21, 596 (2021).
pubmed: 34742305 pmcid: 8572430 doi: 10.1186/s12935-021-02290-3
Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202–2211 (2010).
pubmed: 20558371 pmcid: 3306838 doi: 10.1056/NEJMra0804577
Carabet L. A., Rennie P. S. & Cherkasov A. Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches. Int. J. Mol. Sci. 20, 3-32 (2018).
Llombart, V. & Mansour, M. R. Therapeutic targeting of “undruggable” MYC. EBioMedicine 75, 103756 (2022).
pubmed: 34942444 doi: 10.1016/j.ebiom.2021.103756
Marshall, G. M. et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29, 5957–5968 (2010).
pubmed: 20697349 doi: 10.1038/onc.2010.332
Marshall, G. M. et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 7, e1002135 (2011).
pubmed: 21698133 pmcid: 3116909 doi: 10.1371/journal.pgen.1002135
Liu, P. Y. et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20, 503–514 (2013).
pubmed: 23175188 doi: 10.1038/cdd.2012.147
Carter, D. R. et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci. Transl. Med. 7, 312ra176 (2015).
pubmed: 26537256 pmcid: 6207083 doi: 10.1126/scitranslmed.aab1803
Koach, J. et al. Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface. Cancer Res. 79, 5652–5667 (2019).
pubmed: 31501192 doi: 10.1158/0008-5472.CAN-19-1112
Nagy, Z. et al. An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability. Nat. Commun. 12, 1881 (2021).
pubmed: 33767157 pmcid: 7994381 doi: 10.1038/s41467-021-22143-x
Carpinelli, M. R. et al. Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc. Natl Acad. Sci. USA 101, 6553–6558 (2004).
pubmed: 15071178 pmcid: 404083 doi: 10.1073/pnas.0401496101
Kile, B. T. & Hilton, D. J. The art and design of genetic screens: mouse. Nat. Rev. Genet. 6, 557–567 (2005).
pubmed: 15951745 doi: 10.1038/nrg1636
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 584–587 (2021).
Ooi, C. Y. et al. Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN. Cancer Res. 78, 3122–3134 (2018).
pubmed: 29610116 doi: 10.1158/0008-5472.CAN-17-3034
Ji, H. et al. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS ONE 6, e26057–e26057 (2011).
pubmed: 22039435 pmcid: 3198433 doi: 10.1371/journal.pone.0026057
Zeid, R. et al. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat. Genet. 50, 515–523 (2018).
pubmed: 29379199 pmcid: 6310397 doi: 10.1038/s41588-018-0044-9
Attiyeh, E. F. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243–2253 (2005).
pubmed: 16306521 doi: 10.1056/NEJMoa052399
Luttikhuis, M. E. et al. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br. J. Cancer 85, 531–537 (2001).
pubmed: 11506492 pmcid: 2364087 doi: 10.1054/bjoc.2001.1960
Plantaz, D. et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int. J. Cancer 91, 680–686 (2001).
pubmed: 11267980 doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R
Spitz, R., Hero, B., Simon, T. & Berthold, F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin. Cancer Res. 12, 3368 (2006).
pubmed: 16740759 doi: 10.1158/1078-0432.CCR-05-2495
Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279–284 (2013).
pubmed: 23334666 pmcid: 3682833 doi: 10.1038/ng.2529
Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503–508 (2019).
pubmed: 31068700 pmcid: 6697103 doi: 10.1038/s41586-019-1186-3
Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
pubmed: 29083409 pmcid: 5709193 doi: 10.1038/ng.3984
Kocak, H. et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis. 4, e586 (2013).
pubmed: 23579273 pmcid: 3668636 doi: 10.1038/cddis.2013.84
Wang, C. et al. The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. Nat. Biotechnol. 32, 926–932 (2014).
pubmed: 25150839 pmcid: 4243706 doi: 10.1038/nbt.3001
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095
Pérez Sayáns, M. et al. Comprehensive genomic review of TCGA head and neck squamous cell carcinomas (HNSCC). J. Clin. Med. 8, 7-9 (2019).
Huang, M. & Weiss, W. A. Neuroblastoma and MYCN. Cold Spring Harb. Perspect. Med. 3, a014415 (2013).
pubmed: 24086065 pmcid: 3784814 doi: 10.1101/cshperspect.a014415
Xu, H. et al. E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability. Cell Death Dis. 12, 239 (2021).
pubmed: 33664240 pmcid: 7933351 doi: 10.1038/s41419-021-03521-1
Lipkowitz, S. & Weissman, A. M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 11, 629–643 (2011).
pubmed: 21863050 pmcid: 3542975 doi: 10.1038/nrc3120
Liu, J. et al. The role of the Golgi apparatus in disease. Int. J. Mol. Med. 47, 1-2 (2021).
Mijaljica, D., Prescott, M. & Devenish, R. J. Endoplasmic reticulum and Golgi complex: contributions to, and turnover by, autophagy. Traffic 7, 1590–1595 (2006).
pubmed: 17040485 doi: 10.1111/j.1600-0854.2006.00495.x
Scott, K. L. et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459, 1085–1090 (2009).
pubmed: 19553991 pmcid: 2753613 doi: 10.1038/nature08109
Rizzo, R. et al. Golgi maturation-dependent glycoenzyme recycling controls glycosphingolipid biosynthesis and cell growth via GOLPH3. EMBO J. 40, e107238 (2021).
pubmed: 33749896 pmcid: 8047446 doi: 10.15252/embj.2020107238
Frappaolo, A. et al. GOLPH3 protein controls organ growth by interacting with TOR signaling proteins in Drosophila. Cell Death Dis. 13, 1003 (2022).
pubmed: 36435842 pmcid: 9701223 doi: 10.1038/s41419-022-05438-9
Palm, W. GOLPH3 tunes up glycosphingolipid biosynthesis for cell growth. EMBO J. 40, e108070 (2021).
pubmed: 33763859 pmcid: 8047436 doi: 10.15252/embj.2021108070
Huang, A. et al. Golgi phosphoprotein 3 promotes colon cancer cell metastasis through STAT3 and integrin α3 pathways. Front. Mol. Biosci. 9, 808152 (2022).
pubmed: 35372504 pmcid: 8968920 doi: 10.3389/fmolb.2022.808152
Spano, D. & Colanzi, A. Golgi complex: a signaling hub in cancer. Cells 11, 1-6 (2022).
Gustafson, W. C. & Weiss, W. A. Myc proteins as therapeutic targets. Oncogene 29, 1249–1259 (2010).
pubmed: 20101214 pmcid: 2904682 doi: 10.1038/onc.2009.512
Ruiz-Pérez, M. V., Henley, A. B. & Arsenian-Henriksson, M. The MYCN protein in health and disease. Genes 8, 2-13 (2017).
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J. & Parker, M. W. Oncogenic protein interfaces: small molecules, big challenges. Nat. Rev. Cancer 14, 248–262 (2014).
pubmed: 24622521 doi: 10.1038/nrc3690
Brady, S. W. et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nat. Commun. 11, 5183 (2020).
pubmed: 33056981 pmcid: 7560655 doi: 10.1038/s41467-020-18987-4
Huang, J. et al. Prognostic significance of c-MYC amplification in esophageal squamous cell carcinoma. Ann. Thorac. Surg. 107, 436–443 (2019).
pubmed: 30273571 doi: 10.1016/j.athoracsur.2018.07.077
Zhao, S. et al. Identification and validation of the role of c-Myc in head and neck squamous cell carcinoma. Front. Oncol. 12, 820587 (2022).
pubmed: 36119473 pmcid: 9470836 doi: 10.3389/fonc.2022.820587
Hsieh, J. C. et al. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. Head Neck 41 (Suppl 1), 19–45 (2019).
Aldape, WeissW. A., Mohapatra, K., Feuerstein, G. & Bishop, B. G. JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985–2995 (1997).
pubmed: 9214616 pmcid: 1169917 doi: 10.1093/emboj/16.11.2985
Bode, V. C. Ethylnitrosourea mutagenesis and the isolation of mutant alleles for specific genes located in the T region of mouse chromosome 17. Genetics 108, 457–470 (1984).
pubmed: 6500258 pmcid: 1202417 doi: 10.1093/genetics/108.2.457
Salinger, A. P. & Justice, M. J. Mouse mutagenesis using N-ethyl-N-nitrosourea (ENU). CSH Protoc. 2008, pdb.prot4985 (2008).
Kueh, A. J. et al. An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles. Cell Death Differ. 24, 1821–1822 (2017).
pubmed: 28753205 pmcid: 5596424 doi: 10.1038/cdd.2017.122
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Su, Z. et al. An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era. Genome Biol. 15, 523 (2014).
pubmed: 25633159 doi: 10.1186/s13059-014-0523-y

Auteurs

Belamy B Cheung (BB)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia. bcheung@ccia.unsw.edu.au.
School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia. bcheung@ccia.unsw.edu.au.
ORCID: 0000-0001-8784-860X

Ritu Mittra (R)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Jayne Murray (J)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Qian Wang (Q)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
ORCID: 0000-0002-6514-3470

Janith A Seneviratne (JA)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
ORCID: 0000-0003-0413-5829

Mukesh Raipuria (M)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Iris Poh Ling Wong (IPL)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

David Restuccia (D)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Andrew Gifford (A)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
ORCID: 0000-0002-4092-2347

Alice Salib (A)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Selina Sutton (S)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Libby Huang (L)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
ORCID: 0000-0001-7398-0570

Parisa Vahidi Ferdowsi (PV)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Joanna Tsang (J)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Eric Sekyere (E)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.

Chelsea Mayoh (C)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
ORCID: 0000-0002-6398-3046

Lin Luo (L)

Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
ORCID: 0000-0001-5556-7096

Darren L Brown (DL)

Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.

Jennifer L Stow (JL)

Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
ORCID: 0000-0002-5409-9101

Shizhen Zhu (S)

Department of Biochemistry and Molecular Biology, Cancer Center and Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
ORCID: 0000-0002-2929-3279

Richard J Young (RJ)

Peter MacCallum Cancer Centre, Melbourne, Australia.

Benjamin J Solomon (BJ)

Peter MacCallum Cancer Centre, Melbourne, Australia.
ORCID: 0000-0003-3059-5730

Stephane Chappaz (S)

Anatomy & Developmental Biology, Monash University, Melbourne, Australia.
ORCID: 0000-0003-0574-7544

Benjamin Kile (B)

Faculty of Health and Medical Sciences at the University of Adelaide, Adelaide, Australia.

Andrew Kueh (A)

Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute, Melbourne, Australia.
Department of Medical Biology, The University of Melbourne, Victoria, 3052, Australia.

Marco J Herold (MJ)

Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute, Melbourne, Australia.
Department of Medical Biology, The University of Melbourne, Victoria, 3052, Australia.

Douglas J Hilton (DJ)

Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute, Melbourne, Australia.
Department of Medical Biology, The University of Melbourne, Victoria, 3052, Australia.

Tao Liu (T)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
University of New South Wales Centre for Childhood Cancer Research, Sydney, NSW 2052, Australia.
ORCID: 0000-0001-6244-7316

Murray D Norris (MD)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
University of New South Wales Centre for Childhood Cancer Research, Sydney, NSW 2052, Australia.

Michelle Haber (M)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.

Daniel R Carter (DR)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
School of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.
ORCID: 0000-0002-8464-238X

Michael W Parker (MW)

ACRF Facility for Innovative Cancer Drug Discovery and Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.
ACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
ORCID: 0000-0002-3101-1138

Glenn M Marshall (GM)

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia. glenn.marshall@health.nsw.gov.au.
Kids Cancer Centre, Sydney Children's Hospital, Sydney, 2031, NSW, Australia. glenn.marshall@health.nsw.gov.au.
ORCID: 0000-0002-2503-0762

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Tumeurs neuroectodermiques primitives › Tumeurs neuroectodermiques primitives périphériques › Neuroblastome › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines › Protéine du proto-oncogène N-Myc › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Eucaryotes › Animaux › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Carcinogenèse › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Cellules › Structures cellulaires › Espace intracellulaire › Cytoplasme › Structures cytoplasmiques › Organites › Appareil de Golgi › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Golgi-localized Ring Finger Protein 121 is...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Golgi-localized Ring Finger Protein 121 is...